Pharmafile Logo
Pharmafocus logo
Advanced Search

AZ

Showing 15 posts of 79 posts found.

AstraZeneca takes $445m hit to halt motavizumab

December 22, 2010
Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus

AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …

News
AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor)

FDA delays approval of AstraZeneca’s Brilinta

December 20, 2010
Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome

US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …

News

AZ’s Brilique approved in Europe

December 7, 2010
Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor

European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …

News

AstraZeneca staff strike as pension talks breakdown

November 15, 2010
Manufacturing and Production AZ, AstraZeneca, AstraZeneca UK Manufacturing, GMB, Hurdsfield Industrial Estate, pensions, strikes, unions

Workers at an AstraZeneca facility in the UK went back on strike for the eighth time last week after talks …

News

AstraZeneca dodges another Seroquel lawsuit

April 8, 2010
Sales and Marketing AZ, Seroquel, US

AstraZeneca has defeated another US lawsuit seeking compensation for diabetes side-effects allegedly caused by its drug Seroquel. A US Federal …

News

AstraZeneca signs generics deal with Torrent

March 11, 2010
AZ, generics

AstraZeneca have signed a license and supply agreement with Indian-based Torrent Pharma that will boost its generics portfolio. Torrent will …

News

Recentin disappoints in colorectal cancer

March 9, 2010
Research and Development AZ, Cancer, Recentin, colorectal cancer

AstraZeneca’s developmental oncology drug Recentin has failed to meet its primary endpoint in a phase II/III study. The once-daily oral …

News

AstraZeneca signs deal with Rigel on RA treatment

February 17, 2010
Research and Development AZ, Rigel, rheumatoid arthritis

AstraZeneca is looking to enter the lucrative rheumatoid arthritis market by in-licensing a phase II treatment.The global market for rheumatoid …

News
AlderleyHouseWebv

AZ licences late-stage depression candidate

December 8, 2009
Sales and Marketing AZ, Targacept, depression

AstraZeneca is to pay $200 million up front for rights to a late-stage developmental drug aimed at sufferers from depression …

News

Edelman wins AstraZeneca oncology account

November 24, 2009
Medical Communications AZ, Edelman

AstraZeneca has handed global PR responsibility for its oncology brands to communications agency Edelman. The deal includes the pharma company’s …

News

AstraZeneca withdraws filings for lung cancer drug

November 2, 2009
Research and Development, Sales and Marketing AZ, zactima

AstraZeneca has withdrawn marketing applications for its lung cancer drug Zactima in Europe and the US after evaluating updated results …

News

AZ-BMS launch Onglyza in Europe

October 19, 2009
Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes

 Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …

News

AZ signs biomarker research deal

October 5, 2009
Research and Development AZ, Cancer

A deal between AstraZeneca and Cancer Research UK is set to expand biomarker research into how new drugs behave in …

News

Chop and change for pharma production facilities

September 28, 2009
Manufacturing and Production AZ, Teva

 

News

AZ strikes drug development deal with Nektar Therapeutics

September 22, 2009
Research and Development AZ, Nektar

 AstraZeneca has licenced two anti-constipation drug development programmes from Nektar Therapeutics in a deal that could be worth more than …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026